PE20120998A1 - Metodos para el tratamiento del cancer usando antagonistas de notch - Google Patents
Metodos para el tratamiento del cancer usando antagonistas de notchInfo
- Publication number
- PE20120998A1 PE20120998A1 PE2012000413A PE2012000413A PE20120998A1 PE 20120998 A1 PE20120998 A1 PE 20120998A1 PE 2012000413 A PE2012000413 A PE 2012000413A PE 2012000413 A PE2012000413 A PE 2012000413A PE 20120998 A1 PE20120998 A1 PE 20120998A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- methods
- treating cancer
- cdr
- heavy
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003540 gamma secretase inhibitor Substances 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 208000000389 T-cell leukemia Diseases 0.000 abstract 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UN METODO DE TRATAMIENTO DE LEUCEMIA DE CELULAS T TAL COMO LEUCEMIA LINFOBLASTICA SENSIBLE A LOS INHIBIDORES DE LA GAMMA-SECRETASA (GSI), EL CUAL COMPRENDE ADMINISTRAR A UN PACIENTE i) UNA CANTIDAD DE UN ANTAGONISTA DE Notch3 QUE ES UN ANTICUERPO ANTI-Notch3 NRR QUE COMPRENDE LAS CDR DE LA REGION VARIABLE DE LA CADENA PESADA Y LIGERA DEL ANTICUERPO 256A-4 O 256A-8, Y ii) UNA CANTIDAD DE UN ANTAGONISTA DE Notch1 QUE ES UN ANTICUERPO ANTI-Notch1 NRR QUE COMPRENDE LAS CDR DE LA REGION VARIABLE DE LA CADENA PESADA Y LIGERA DEL ANTICUERPO A, A-1, A-2 O A-3. TAMBIEN SE REFIERE A UN METODO PARA LA IDENTIFICACION DE UN CANCER ADECUADO PARA EL TRATAMIENTO CON UN ANTAGONISTA DE Notch3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24729809P | 2009-09-30 | 2009-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120998A1 true PE20120998A1 (es) | 2012-08-14 |
Family
ID=43127684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000413A PE20120998A1 (es) | 2009-09-30 | 2010-09-29 | Metodos para el tratamiento del cancer usando antagonistas de notch |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9200071B2 (es) |
| EP (1) | EP2483311B1 (es) |
| JP (3) | JP6025563B2 (es) |
| KR (1) | KR101782180B1 (es) |
| CN (1) | CN102630229B (es) |
| AU (1) | AU2010300747A1 (es) |
| BR (1) | BR112012007252A2 (es) |
| CA (1) | CA2775880A1 (es) |
| CL (1) | CL2012000800A1 (es) |
| CO (1) | CO6531430A2 (es) |
| CR (1) | CR20120213A (es) |
| EC (1) | ECSP12011858A (es) |
| ES (1) | ES2580229T3 (es) |
| IL (1) | IL218662A0 (es) |
| MA (1) | MA33973B1 (es) |
| MX (1) | MX342250B (es) |
| PE (1) | PE20120998A1 (es) |
| PH (1) | PH12012500574A1 (es) |
| RU (1) | RU2012117619A (es) |
| WO (1) | WO2011041336A2 (es) |
| ZA (1) | ZA201201984B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2133796C1 (ru) * | 1997-10-09 | 1999-07-27 | ОАО "Томский электромеханический завод им.В.В.Вахрушева" | Люк смотрового колодца |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| AU2008209482B2 (en) | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| NZ590127A (en) | 2008-07-08 | 2012-11-30 | Oncomed Pharm Inc | Notch1 receptor binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102686610A (zh) | 2009-06-18 | 2012-09-19 | 辉瑞公司 | 抗刻缺蛋白-1抗体 |
| BR112013015122A2 (pt) | 2010-12-15 | 2017-05-30 | Wyeth Llc | anticorpos anti-notch1 |
| CN104903351A (zh) | 2012-11-07 | 2015-09-09 | 辉瑞公司 | 抗-notch3抗体及抗体-药物缀合物 |
| WO2014100435A1 (en) | 2012-12-19 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibodies |
| EP3611189A1 (en) * | 2013-03-14 | 2020-02-19 | Novartis AG | Antibodies against notch 3 |
| WO2014159242A1 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
| CN105051215A (zh) * | 2013-03-15 | 2015-11-11 | 昂考梅德药品有限公司 | 治疗胰腺癌的方法 |
| WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| SG10201808259TA (en) | 2014-02-12 | 2018-10-30 | Genentech Inc | Anti-jagged1 antibodies and methods of use |
| EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
| DK3448420T3 (da) | 2016-04-29 | 2022-12-12 | Aveo Pharmaceuticals Inc | Anti-notch3-antistof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| JP2008526205A (ja) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Ｂｒ３に結合するポリペプチド及びその使用 |
| KR101525629B1 (ko) | 2006-10-19 | 2015-06-26 | 제넨테크, 인크. | 항-Ｎｏｔｃｈ3 작동제 항체 및 Ｎｏｔｃｈ3 관련 질환을 치료하는 데에 있어서의 그의 용도 |
| WO2008136848A2 (en) | 2006-10-19 | 2008-11-13 | Genentech Inc. | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease |
| BRPI0719409A2 (pt) * | 2006-12-18 | 2014-02-11 | Genentch Inc | "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo" |
| AU2008209482B2 (en) * | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2134356A2 (en) * | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| NZ590127A (en) * | 2008-07-08 | 2012-11-30 | Oncomed Pharm Inc | Notch1 receptor binding agents and methods of use thereof |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| CN102686610A (zh) * | 2009-06-18 | 2012-09-19 | 辉瑞公司 | 抗刻缺蛋白-1抗体 |
-
2010
- 2010-09-29 RU RU2012117619/10A patent/RU2012117619A/ru not_active Application Discontinuation
- 2010-09-29 MX MX2012003851A patent/MX342250B/es active IP Right Grant
- 2010-09-29 CA CA2775880A patent/CA2775880A1/en not_active Abandoned
- 2010-09-29 JP JP2012532248A patent/JP6025563B2/ja active Active
- 2010-09-29 BR BR112012007252-8A patent/BR112012007252A2/pt not_active IP Right Cessation
- 2010-09-29 WO PCT/US2010/050610 patent/WO2011041336A2/en not_active Ceased
- 2010-09-29 US US13/498,560 patent/US9200071B2/en active Active
- 2010-09-29 EP EP10762827.3A patent/EP2483311B1/en active Active
- 2010-09-29 MA MA34797A patent/MA33973B1/fr unknown
- 2010-09-29 PE PE2012000413A patent/PE20120998A1/es not_active Application Discontinuation
- 2010-09-29 CN CN201080054108.9A patent/CN102630229B/zh active Active
- 2010-09-29 KR KR1020127010886A patent/KR101782180B1/ko not_active Expired - Fee Related
- 2010-09-29 AU AU2010300747A patent/AU2010300747A1/en not_active Abandoned
- 2010-09-29 ES ES10762827.3T patent/ES2580229T3/es active Active
- 2010-09-29 PH PH1/2012/500574A patent/PH12012500574A1/en unknown
-
2012
- 2012-03-15 IL IL218662A patent/IL218662A0/en unknown
- 2012-03-16 ZA ZA2012/01984A patent/ZA201201984B/en unknown
- 2012-03-30 CL CL2012000800A patent/CL2012000800A1/es unknown
- 2012-04-09 CO CO12057624A patent/CO6531430A2/es not_active Application Discontinuation
- 2012-04-26 CR CR20120213A patent/CR20120213A/es unknown
- 2012-04-30 EC ECSP12011858 patent/ECSP12011858A/es unknown
-
2015
- 2015-01-23 JP JP2015011573A patent/JP2015145362A/ja not_active Withdrawn
-
2016
- 2016-07-13 JP JP2016138236A patent/JP2017014219A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX342250B (es) | 2016-09-22 |
| ECSP12011858A (es) | 2012-06-29 |
| ES2580229T3 (es) | 2016-08-22 |
| JP2013506675A (ja) | 2013-02-28 |
| HK1170505A1 (en) | 2013-03-01 |
| JP2017014219A (ja) | 2017-01-19 |
| EP2483311A2 (en) | 2012-08-08 |
| AU2010300747A1 (en) | 2012-04-26 |
| CN102630229B (zh) | 2015-03-04 |
| IL218662A0 (en) | 2012-05-31 |
| CA2775880A1 (en) | 2011-04-07 |
| CO6531430A2 (es) | 2012-09-28 |
| BR112012007252A2 (pt) | 2020-08-11 |
| RU2012117619A (ru) | 2013-11-10 |
| EP2483311B1 (en) | 2016-05-18 |
| CN102630229A (zh) | 2012-08-08 |
| JP2015145362A (ja) | 2015-08-13 |
| CL2012000800A1 (es) | 2012-08-31 |
| US20120328608A1 (en) | 2012-12-27 |
| MA33973B1 (fr) | 2013-02-01 |
| KR20120100952A (ko) | 2012-09-12 |
| KR101782180B1 (ko) | 2017-10-23 |
| JP6025563B2 (ja) | 2016-11-16 |
| WO2011041336A2 (en) | 2011-04-07 |
| ZA201201984B (en) | 2013-05-29 |
| MX2012003851A (es) | 2012-05-08 |
| PH12012500574A1 (en) | 2012-10-22 |
| US9200071B2 (en) | 2015-12-01 |
| CR20120213A (es) | 2012-07-09 |
| WO2011041336A3 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| MX2016007972A (es) | Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos. | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
| UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| MX2011010911A (es) | Terapia de combinacion que usa un agente o agentes anti-receptor del factor de crecimiento epidermico e inhibidores especificos del factor de crecimiento similar a insulina-1r. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |